Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Teita Asano"'
Autor:
Masahiko Miyashiro, Teita Asano, Yutaka Ishii, Celine Miyazaki, Hirohito Shimizu, Junya Masuda
Publikováno v:
Drugs - Real World Outcomes, Vol 11, Iss 2, Pp 285-297 (2024)
Abstract Background Reports on treatment patterns of biologic disease-modifying antirheumatic drugs (bDMARDs)/Janus kinase inhibitors (JAKi) for rheumatoid arthritis (RA) in clinical practice are still sparse in Japan, especially in combination with
Externí odkaz:
https://doaj.org/article/e703f5004a33490ca1ac66a2d9dd6769
Autor:
Shiro Nakamura, Teita Asano, Hiroaki Tsuchiya, Kanami Sugimoto, Yuya Imai, Seiji Yokoyama, Yasuo Suzuki
Publikováno v:
Intestinal Research, Vol 20, Iss 3, Pp 329-341 (2022)
Background/Aims Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in pa
Externí odkaz:
https://doaj.org/article/71e114b21acf4f648efaa0b86a6ec480
Autor:
Shiro Nakamura, Teita Asano, Yoshihito Tanaka, Kanami Sugimoto, Shinichi Yoshigoe, Yasuo Suzuki
Publikováno v:
Inflammatory Intestinal Diseases (2022)
Introduction: Real-world evidence for the effectiveness and safety of golimumab (GLM) in patients with ulcerative colitis (UC) is limited. The aim of this study was to investigate the 52-week effectiveness and safety of GLM treatment for UC. Methods:
Externí odkaz:
https://doaj.org/article/41b73e39759c4bd9b4f987ad46c0f1e2
Autor:
Ken-Ichiro Tanaka, Naoki Yamakawa, Yasunobu Yamashita, Teita Asano, Yuki Kanda, Ayaka Takafuji, Masahiro Kawahara, Mitsuko Takenaga, Yoshifumi Fukunishi, Tohru Mizushima
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
The standard treatment for chronic obstructive pulmonary disease is a combination of anti-inflammatory drugs and bronchodilators. We recently found that mepenzolate bromide (MP), an antagonist for human muscarinic M3 receptor (hM3R), has both anti-in
Externí odkaz:
https://doaj.org/article/5b550f05b51d4e2cb8a9c89e57e463fe
Autor:
Teita Asano, Mitsuko Takenaga
Publikováno v:
Journal of Clinical Medicine, Vol 6, Iss 11, p 104 (2017)
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder, with the characteristic symptoms of chronic abdominal pain and altered bowel habits (diarrhea, constipation, or both). IBS is a highly prevalent condition, which negatively aff
Externí odkaz:
https://doaj.org/article/2cd6089361d44302b68b1279f15bb6e7
Autor:
Katsumasa Nagano, Erina Hata, Teita Asano, Hiroaki Tsuchiya, Masayuki Takagishi, Hiroshi Yamazaki, Sonoko Tominaga, Takayuki Matsumoto
Publikováno v:
Crohn's & Colitis 360. 5
Background To present the real-world evidence on the safety and effectiveness of ustekinumab (UST) through 52-week treatment for Crohn’s disease (CD) under an analysis of post-market surveillance data in Japan. Methods This prospective, post-market
Autor:
Ken Ichiro Tanaka, Teita Asano, Daisuke Kobayashi, Tohru Mizushima, Ayaka Takafuji, Yuuki Hino, Kaoru Mogushi, Toshifumi Sugizaki, Mikako Shimoda, Masahiro Kawahara
Publikováno v:
Cell Death Discovery, Vol 5, Iss 1, Pp 1-15 (2019)
Cell Death Discovery
Cell Death Discovery
Alveolar epithelial injury induced by reactive oxygen species (ROS) and abnormal collagen production by activated fibroblasts (myofibroblasts) is involved in the onset and exacerbation of idiopathic pulmonary fibrosis (IPF). Compared with alveolar ep
Autor:
Takayuki Matsumoto, Katsumasa Nagano, Erina Hata, Teita Asano, Hiroaki Tsuchiya, Masayuki Takagishi, Hiroshi Yamazaki, Sonoko Tominaga
Publikováno v:
Gastroenterology. 162:S-1098
Autor:
Teita Asano1 asano-ti@marianna-u.ac.jp, Mitsuko Takenaga1 m2take@marianna-u.ac.jp
Publikováno v:
Journal of Clinical Medicine. Nov2017, Vol. 6 Issue 11, p104. 10p.
Autor:
Tadaaki Mashimo, Yoshifumi Fukunishi, Mitsuko Takenaga, Tohru Mizushima, Ken Ichiro Tanaka, Mitsuhito Wada, Teita Asano, Yuto Noda, Naoki Yamakawa
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
The adenosine A2B receptor is a critical protein in intestinal water secretion. In the present study, we screened compound libraries to identify inhibitors of the A2B receptor and evaluated their effect on adenosine-induced intestinal fluid secretion